ArticleBlood2017
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 144 citations in OpenAlex.
- Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.Haematologica · 2018Trial
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- ERDHEIM-Chester Disease: Two Fatal Cases With Unusual Presentations.Clinical case reports · 2026Article
- Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.Haematologica · 2026Article
- Erdheim-Chester disease associated with myeloid neoplasm: Clinical features, molecular landscape, and treatment outcomes.HemaSphere · 2026Article
- Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts-a report from the joint CSHP-EA4HP-SH workshop 2024, Hefei, China.Virchows Archiv : an international journal of pathology · 2026Review
- Case Report: Pediatric Erdheim-Chester disease with bilateral chorioretinal and central nervous system infiltration.Frontiers in medicine · 2026Article
- Case Report: Erdheim-Chester disease presenting as abdominal cocoon syndrome.Frontiers in immunology · 2026Article
- Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration.Haematologica · 2025Review
- Juvenile xanthogranuloma as a potential early manifestation of neurofibromatosis type 1: A case report.Medicine · 2025Article
- Multifocal sclerotic lesions in Erdheim-Chester disease successfully treated with tocilizumab.Immunotherapy · 2025Article
- NTRK1-rearranged histiocytosis: clinicopathologic and molecular features.Blood advances · 2025Article
- Article
- Neuroimaging Spectrum of Erdheim-Chester Disease: An Image-Based Review.AJNR. American journal of neuroradiology · 2025Review
- Risk of Second Cancer in Erdheim-Chester Disease.JAMA oncology · 2025Article
- Recurrent ETV3::NCOA2 fusions and MAPK pathway mutations in indeterminate dendritic cell histiocytosis.Blood advances · 2025Article
- IDCH: is it now determined?Blood advances · 2025Article
- Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.Haematologica · 2025Review
- BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature.Journal of hematopathology · 2024Review
- Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations.JCO precision oncology · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 11 institutions in 2 countries.
Matthias PapoService de Médecine Interne 2, Institut E3M, Centre de Références des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Histiocytoses, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
Fleur Cohen-AubartService de Médecine Interne 2, Institut E3M, Centre de Références des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Histiocytoses, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
Jean-François EmileEA4340, Versailles University, Paris-Saclay University, Boulogne, France.
Damien Roos-WeilUMR1170, INSERM and Institute Gustave Roussy, Villejuif, France.
Nishant GuptaDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH.
Benjamin H DurhamDepartment of Pathology.
Neval OzkayaDepartment of Pathology.
Ahmet DoganDepartment of Pathology.
Gary A UlanerDepartment of Radiology, and.
Raajit RampalLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Jean-Emmanuel KahnDepartment of Internal Medicine, Foch Hospital, Suresnes, France.
Thomas SenéDepartment of Internal Medicine, Croix Saint-Simon Hospital, Paris, France.
Frédéric CharlotteDepartment of Pathology.
Baptiste HervierDepartment of Internal Medicine and Immunology, and.
Caroline BesnardService de Médecine Interne 2, Institut E3M, Centre de Références des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Histiocytoses, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
Olivier A BernardUMR1170, INSERM and Institute Gustave Roussy, Villejuif, France.
Catherine SettegranaDepartment of Biological Hematology, University Hospital La Pitié Salpêtrière, AP-HP, Paris, France.
Nathalie DroinGustave Roussy, Paris-Saclay University, Genomic Platform UMS AMMICA, Villejuif, France; and.
Zofia Hélias-RodzewiczEA4340, Versailles University, Paris-Saclay University, Boulogne, France.
Zahir AmouraService de Médecine Interne 2, Institut E3M, Centre de Références des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Histiocytoses, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
Omar Abdel-WahabLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Julien HarocheService de Médecine Interne 2, Institut E3M, Centre de Références des Maladies Auto-Immunes et Systémiques Rares, Centre de Référence des Histiocytoses, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
Memorial Sloan Kettering Cancer Center · USSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRPitié-Salpêtrière Hospital · FRGroupe Hospitalier Diaconesses Croix Saint-Simon · FRHôpital Ambroise-Paré · FRHôpital Foch · FRInserm · FRInstitut Gustave Roussy · FRUniversité Paris-Saclay · FRUniversity of Cincinnati · US
Funding
Genetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MRLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung DiseasesU54HL127672 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI TRAPNELL, BRUCE C · 2014 to 2018
$3.7MOrigins of BRAF-mutant hematologic malignancies and their therapeutic resistanceR01CA201247 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, PARK, CHRISTOPHER Y · 2016 to 2020
$2.7MGenomic profiling and development of murine models of transformation of MPNsK08CA188529 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RAMPAL, RAAJIT · 2014 to 2018
$891kRole of ASXL1 mutations in myeloid malignanciesK08CA160647 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR · 2011 to 2015
$849kNCI NIH HHS K08 CA160647NCI NIH HHS K08 CA188529NCI NIH HHS R01 CA201247NHLBI NIH HHS R01 HL128239NHLBI NIH HHS U54 HL127672
Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects adults and is driven by a high frequency of mutations in
Indexed as
AdultAgedBone Marrow NeoplasmsErdheim-Chester DiseaseFemaleHistiocytosis, Non-Langerhans-CellHumansMaleMiddle AgedMolecular Targeted TherapyPrevalence
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.